Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Kevin Peng

Otology & Neurotology Los Angeles, CA Medical Doctor

NPI 1245556653 CMS profile 1395160

2100 W 3Rd St Ste 111, Ste 480, Los Angeles, CA 90057

Open in the dashboard

General payments

$16,937

55 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kevin Peng of Los Angeles, CA is reported in the CMS Open Payments database as having received $16,937 across 55 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 85th percentile of Otology & Neurotology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,548 15
2024 General $11,696 18
2023 General $269 3
2022 General $280 5
2021 General $361 5
2019 General $782 9

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kevin Peng
  • Otology & Neurotology median
  • Middle half of Otology & Neurotology
  • National median

In program year 2025, general payments to Kevin Peng were reported at $3,548. Among 280 Otology & Neurotology profiles paid that year, the median was $411 and the middle half received between $148 and $1,608.

Show as a table
Year Kevin Peng Otology & Neurotology median Middle half National median
2019 $782 $349 $117–$1,358 $163
2020 $0 $118 $58–$325 $114
2021 $361 $186 $81–$600 $132
2022 $280 $290 $129–$938 $149
2023 $269 $335 $119–$978 $160
2024 $11,696 $399 $138–$1,384 $164
2025 $3,548 $411 $148–$1,608 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $13,715 18 payments
  2. Cochlear Americas $1,132 15 payments
  3. MED-EL Corporation $893 4 payments
  4. Acclarent, Inc $394 5 payments
  5. Integra LifeSciences Corporation $216 4 payments
  6. AxoGen $134 2 payments
  7. Baxter Healthcare $125 1 payment
  8. Smith+Nephew, Inc. $123 2 payments
  9. Stryker Corporation $115 1 payment
  10. Advanced Bionics, LLC $62 2 payments
  11. Other $28 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $11,550 3 payments
  2. Travel and Lodging $2,720 16 payments
  3. Food and Beverage $2,668 36 payments
Products named General payments · program years 2019–2025
  1. NIM-RESPONSE $10,799 12 payments
  2. Mi1250 SYNCHRONY 2 FLEXsoft $807 3 payments
  3. ADHEAR Professional Kit $807 3 payments
  4. BCI 602 Kit $807 3 payments
  5. Nucleus $759 8 payments
  6. Baha Implantable hearing solution $759 8 payments
  7. NIM Vital $374 3 payments
  8. Cochlear Nucleus CI632 cochlear implant with Slim Modiolar electrode $349 6 payments
  9. TruDi NAV Cable $254 3 payments
  10. BAHA Implantable hearing solution $231 5 payments
  11. Other $2,458 43 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

371

Median for Otolaryngology: 297

Drug cost

$12,800

Median for Otolaryngology: $6,314

Branded share of claims

42.6%

Median for Otolaryngology: 10.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ciprofloxacin-Dexamethasone Ciprofloxacin Hcl/Dexameth Brand 83 $9,938
Clobetasol Propionate Generic 42 $1,234
Potassium Chloride Generic 24 $433
Triamterene-Hydrochlorothiazid Triamterene/Hydrochlorothiazid Brand 58 $359
Nortriptyline Hcl Generic 38 $206
Fluticasone Propionate Generic 21 $165
Venlafaxine Hcl Er Venlafaxine Hcl Brand 17 $108
Methylprednisolone Generic 18 $98
Prednisone Generic 23 $85
Montelukast Sodium Generic 13 $61

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,296 Part D prescribers listed as Otolaryngology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 52 billing codes

Paid by Medicare

$222,200

Medicare's payments for the services billed

Medicare patients

554

Average age 74

Services billed

5,580

317 women, 237 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 71%
Arthritis 51%
Ischemic heart disease 29%
Diabetes 27%
Osteoporosis 21%
Chronic kidney disease 19%
Depression 18%
Cancer 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

55 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Otology & Neurotology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record